Gout Treatment: Acute and Long-Term Management

Acute Gout Flare Management

Initiate anti-inflammatory therapy within 24 hours of symptom onset using NSAIDs, low-dose colchicine, or corticosteroids as first-line options; all three are equally effective, and choice should be based on contraindications and cost. 1, 2

First-Line Treatment Options

NSAIDs should be administered at full anti-inflammatory doses (e.g., naproxen 500 mg twice daily or indomethacin 50 mg three times daily) and continued until complete flare resolution, typically 5–14 days. 1, 2
Low-dose colchicine (1.2 mg immediately, then 0.6 mg one hour later, maximum 1.8 mg total) provides pain relief equivalent to higher doses but with significantly fewer gastrointestinal adverse effects. 3, 1, 4
Corticosteroids are appropriate when NSAIDs or colchicine are contraindicated: oral prednisone 30–40 mg daily for 5–10 days, intramuscular triamcinolone 60 mg, or intra-articular injection for monoarticular attacks. 1, 2, 4

Critical Timing Considerations

Treatment delayed beyond 24 hours significantly reduces effectiveness regardless of agent selected. 1, 2
Low-dose colchicine initiated after 36 hours loses efficacy. 2
Goal: ≥20% pain reduction within 24 hours and ≥50% reduction by 48 hours; if <20% improvement at 24 hours, add a second agent or switch therapy. 1

Management of Existing Urate-Lowering Therapy

Never discontinue established urate-lowering therapy (allopurinol or febuxostat) during an acute flare; continuation prevents symptom prolongation and preserves long-term urate control. 1, 2, 4
Do not initiate urate-lowering therapy during a first gout attack or any acute flare; defer until the attack has completely resolved. 1, 2

Long-Term Urate-Lowering Therapy (ULT)

Absolute Indications for Starting ULT

Begin urate-lowering therapy in patients with any of the following: 1, 2

≥2 gout attacks per year
Presence of tophi (clinical or radiographic)
Chronic kidney disease stage ≥3
History of uric acid kidney stones
Radiographic joint damage from gout

Contraindications to ULT Initiation

Do not start ULT after a single gout attack in the absence of high-risk features (tophi, CKD, stones). 3, 1
Do not initiate ULT in patients with <2 attacks per year unless tophi, CKD, or other high-risk features are present. 3, 1

Urate-Lowering Drug Selection and Dosing

First-Line Agent: Allopurinol

Allopurinol is the preferred first-line urate-lowering medication. 1, 2, 4

Starting dose: 100 mg daily in patients with normal renal function; 50 mg daily in chronic kidney disease stage 4 or worse. 2, 5
Titration: Increase by 100 mg every 2–5 weeks (weekly intervals acceptable per FDA labeling) until serum urate <6 mg/dL. 1, 2, 5
Maximum dose: 800 mg daily. 2, 5
Renal dosing: With creatinine clearance 10–20 mL/min, use 200 mg daily; with CrCl <10 mL/min, do not exceed 100 mg daily. 1, 5

Alternative Agent: Febuxostat

Febuxostat 40 mg daily lowers serum urate as effectively as allopurinol 300 mg daily. 3, 1
Use febuxostat when allopurinol is contraindicated, not tolerated, or ineffective after adequate dose titration. 1, 4
Common adverse effects include abdominal pain, diarrhea, and musculoskeletal pain. 3, 1

Treat-to-Target Strategy

All patients receiving urate-lowering therapy must be titrated to achieve a serum urate target <6 mg/dL (360 µmol/L); this treat-to-target approach is superior to fixed-dose regimens. 1, 2

Monitor serum urate every 2–5 weeks during dose titration. 2, 4
Some patients with tophi may require a target <5 mg/dL for tophus resolution. 2

Mandatory Anti-Inflammatory Prophylaxis During ULT Initiation

All patients starting urate-lowering therapy must receive concomitant anti-inflammatory prophylaxis; omission dramatically increases flare risk and leads to treatment abandonment. 1, 2, 4

Why Prophylaxis Is Essential

Urate-lowering therapy does not reduce gout attacks during the first 6 months and may initially increase flare frequency due to mobilization of urate from tissue deposits. 3, 1
After 1 year, patients achieving serum urate <6 mg/dL have progressively fewer attacks. 1

First-Line Prophylaxis Options

Agent	Typical Dose
Colchicine (low-dose)	0.5–0.6 mg once or twice daily
NSAID (e.g., naproxen)	250 mg twice daily
Corticosteroid (if colchicine/NSAID contraindicated)	Prednisone 5–10 mg daily

1, 2, 4

Duration of Prophylaxis

Minimum duration: 3 months after ULT initiation. 1, 2
Optimal duration: 3–6 months, or until serum urate target is achieved and the patient remains flare-free. 1, 2
Prophylaxis extending beyond 8 weeks is significantly more effective; flares approximately double when stopped after only 8 weeks. 3, 1
Extend prophylaxis beyond 6 months if flares persist or the serum urate target has not been reached. 1

Dose Adjustments for Renal Impairment

With creatinine clearance <50 mL/min, reduce colchicine prophylaxis to 0.3 mg once daily. 2
Avoid NSAIDs in severe renal impairment (CrCl <30 mL/min). 2

Algorithmic Approach to Gout Management

For an Acute Flare:

Start anti-inflammatory therapy within 24 hours: NSAID, low-dose colchicine, or corticosteroid. 1, 2
Continue any established urate-lowering therapy without interruption. 1, 2
Maintain anti-inflammatory therapy at full dose until complete symptom resolution. 1, 2
For severe polyarticular attacks (pain >6/10, multiple large joints), combine two agents from different classes (e.g., corticosteroid + colchicine). 2

For Long-Term Management:

Determine if ULT is indicated (≥2 attacks/year, tophi, CKD ≥3, stones, radiographic damage). 1, 2
Start allopurinol 100 mg daily (50 mg if CKD stage 4+) and simultaneously start prophylaxis with low-dose colchicine or NSAID. 1, 2
Titrate allopurinol every 2–5 weeks by 100 mg increments until serum urate <6 mg/dL. 1, 2
Continue prophylaxis for minimum 3 months, optimally 3–6 months, or until attack-free with target achieved. 1, 2
Monitor serum urate every 2–5 weeks during titration, then periodically to ensure target maintenance. 2, 4

Common Pitfalls and How to Avoid Them

Never initiate ULT without concurrent anti-inflammatory prophylaxis; this virtually guarantees flares and treatment abandonment. 1, 2
Never discontinue prophylaxis before 3 months; premature cessation leads to preventable flares. 1, 2
Never use a fixed-dose ULT regimen without monitoring and titration; treat-to-target is superior. 1
Never delay acute flare treatment beyond 24 hours; effectiveness is significantly compromised. 1, 2
Never stop established ULT during an acute flare; this prolongs the attack and destabilizes urate control. 1, 2
Never use high-dose colchicine (1.2 mg followed by 0.6 mg hourly); it provides no additional efficacy but markedly increases gastrointestinal toxicity compared with the low-dose regimen (1.8 mg total). 1, 2
Never undertitrate allopurinol; doses above 300 mg daily are safe and often necessary to achieve target serum urate, even in renal impairment with appropriate monitoring. 2, 4

Cost Considerations

When no contraindications exist, select among NSAIDs, colchicine, and corticosteroids based on cost; colchicine (including generic formulations) is the most expensive option. 3, 1

Lifestyle Modifications

Encourage weight reduction in overweight or obese individuals. 1, 2
Advise limiting alcohol intake, especially beer and spirits. 1, 2
Recommend avoiding sugar-sweetened beverages and high-fructose corn syrup. 1, 2
Suggest reducing consumption of organ meats and shellfish. 1, 2
Promote intake of low-fat dairy products and a diet rich in vegetables. 1, 2

What is the appropriate acute and long‑term treatment plan for an adult with gout?

Help us tailor your experience